Dermal therapeutic system with high adhesivity

A dermal therapeutic system which comprises an adhesive polymeric matrix comprising

• an acrylate-vinyl acetate copolymer having a Tg below 0° C., which contains free hydroxyl groups, said acrylate-vinyl acetate copolymer being present in a percentage ranging from 45 to 65% by weight with respect to the total dry weight of the adhesive polymeric matrix and a basic butylated methacrylate copolymer, said basic butylated methacrylate copolymer being present in a percentage ranging from 5 to 20% by weight with respect to the total dry weight of the adhesive polymeric matrix, as adhesive components,
• an organic or inorganic acid in a percentage ranging from 0.5 to 3.5% by weight with respect to the total dry weight of the adhesive polymeric matrix, as stabilizer,
• a salt of Diclofenac in a percentage ranging from 8 to 20% by weight with respect to the total dry weight of the adhesive polymeric matrix, as active principle,
• an adhesion modulator in a percentage ranging from 10 to 30% by weight with respect to the total dry weight of the adhesive polymeric matrix, and
• the complement to 100 consisting of excipients and/or pharmaceutically acceptable additives,
• wherein said dermal therapeutic system does not allow said salt of Diclofenac to exert a systemic action,
• wherein the acrylate-vinyl acetate copolymer having a Tg below 0° C., containing free hydroxyl groups, is a self-curing acrylate-vinyl acetate copolymer having a Tg lower than 0° C., containing free hydroxyl groups and without free carboxyl groups or a non-curing acrylate-vinyl acetate copolymer having a Tg lower than 0° C., containing free hydroxyl groups and without free carboxyl groups;
• wherein the salt of Diclofenac is selected from the group consisting of alkaline metal salts of Diclofenac, hydroxyethylpyrrolidine salt of Diclofenac, and diethylammonium salt of Diclofenac;
• wherein the inorganic acid is hydrochloric acid;
• wherein the organic acid is selected from the group consisting of citric acid, succinic acid, lactic acid, maleic acid, fumaric acid, salicylic acid, acetic acid, and a mixture thereof;
• wherein the adhesive polymeric matrix has a thickness ranging from 50 to 500 microns and
• wherein the dermal therapeutic system has a surface ranging from 20 to 300 cm2.